0001140361-24-017909.txt : 20240404
0001140361-24-017909.hdr.sgml : 20240404
20240404151419
ACCESSION NUMBER: 0001140361-24-017909
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06c
FILED AS OF DATE: 20240404
DATE AS OF CHANGE: 20240404
EFFECTIVENESS DATE: 20240404
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacylex Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001866841
ORGANIZATION NAME:
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-509694
FILM NUMBER: 24822895
BUSINESS ADDRESS:
STREET 1: 400 3RD AVENUE SW, SUITE 3700
CITY: CALGARY
STATE: A0
ZIP: T2P 4H2
BUSINESS PHONE: 780-264-4295
MAIL ADDRESS:
STREET 1: 400 3RD AVENUE SW, SUITE 3700
CITY: CALGARY
STATE: A0
ZIP: T2P 4H2
D
1
primary_doc.xml
X0708
D
LIVE
0001866841
Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW
Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
780-264-4295
CANADA (FEDERAL LEVEL)
None
None
Corporation
true
Cindy
Jacobs
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
Director
Mark
Huson
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
Director
Michael
Weickert
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
Director
Executive Officer
Luc
G.
Berthiaume
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A1
BRITISH COLUMBIA, CANADA
T2P 4H2
Director
John
Mackey
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
Director
Ryan
Heit
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
Executive Officer
Ajit
Gill
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
Director
Nola
Masterson
c/o Pacylex Pharmaceuticals Inc.
400 3rd Avenue SW, Suite 3700
Calgary
A0
ALBERTA, CANADA
T2P 4H2
Director
Pharmaceuticals
Decline to Disclose
- 06c
false
2024-03-21
false
true
true
false
0
75000
75000
0
This filing covers, in part, the sale of common shares issued as a result of the conversion of convertible notes.
false
3
0
0
0
Pacylex Pharmaceuticals Inc.
/s/ Ryan Heit
Ryan Heit
Chief Operating Officer
2024-04-04